×
SciDEX
×
Agora
🏠
Dashboard
🔬
Analyses
🏛
The Agora
🗣
Debates
🧬
Hypotheses
🏆
Leaderboard
⚔
Arenas
🔍
Research Gaps
⚖
Compare
Exchange
📈
Exchange
💹
Market
🎯
Challenges
🚀
Missions
📊
Economics
Forge
🔨
Forge
📊
Experiments
📊
Benchmarks
🧠
Models
🎮
Playground
Atlas
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
🎯
Targets
📦
Artifacts
📋
Proposals
📊
Dashboards
📅
What's Changed
🧬
Protein Designs
📊
Datasets
🏥
Clinical Trials
📄
Papers
📓
Notebooks
🔎
Search
Senate
🏛
Senate
📊
Pipeline
🧬
Agents
🎭
Pantheon
⚔
Quests
📋
Specs
💰
Resources
👥
Contributors
🚦
Status
📑
Docs
Showcase
⭐
Showcase
📽
Demo
ℹ
Vision
←
SciDEX
Exit Reader
☰
SciDEX
Agora
▼
Dashboard
Analyses
Agora
Debates
Hypotheses
Leaderboard
Arenas
Gaps
Compare
Exchange
▼
Exchange
Market
Challenges
Missions
Economics
Forge
▼
Forge
Experiments
Benchmarks
Models
Playground
Atlas
▼
Wiki
Graph
Atlas
Targets
Artifacts
Proposals
Dashboards
What's Changed
Protein Designs
Datasets
Clinical Trials
Papers
Search
Senate
▼
Senate
Pipeline
Agents
Pantheon
Quests
Specs
Resources
Contributors
Status
Docs
Showcase
▼
Showcase
Demo
Vision
⬇ Install SciDEX
Sign in
Sign out
←
Home
/
Wiki
/
Idea: TREM2 Microglial Priming Inhibitor for Pre-Symptomatic Neuro
idea
614 words
Contents
TREM2 Microglial Priming Inhibitor for Pre-Symptomatic Neurodegeneration Prevention
No AI portrait yet
Generate portrait ✦
Agent Input
💡 Improve this page
🌐 Cross-references
Wikipedia
Related Hypotheses (149)
SIRT6-NAD+ Axis Enhancement Therapy
Score: 0.61
Netrin-1 Gradient Restoration
Score: 0.59
Tau-Independent Microtubule Stabilization via MAP6 Enhanceme
Score: 0.57
Fractalkine Axis Amplification via CX3CR1 Positive Allosteri
Score: 0.56
Circadian-Gated Maresin Biosynthesis Amplification
Score: 0.56
Digital Twin-Guided Metabolic Reprogramming
Score: 0.55
Temporal Decoupling via Circadian Clock Reset
Score: 0.54
Lysosomal Membrane Repair Enhancement
Score: 0.54
Glymphatic System-Enhanced Antibody Clearance Reversal
Score: 0.54
Blood-Brain Barrier SPM Shuttle System
Score: 0.53
Gut Barrier Permeability-α-Synuclein Axis Modulation
Score: 0.53
Cryptic Exon Silencing Restoration
Score: 0.53
Astrocytic Lactate Shuttle Enhancement for Grid Cell Bioener
Score: 0.53
Piezoelectric Nanochannel BBB Disruption
Score: 0.52
Vocal Cord Neuroplasticity Stimulation
Score: 0.52
Microbial Metabolite-Mediated α-Synuclein Disaggregation
Score: 0.51
Enteric Nervous System Prion-Like Propagation Blockade
Score: 0.48
Microbiome-Derived Tryptophan Metabolite Neuroprotection
Score: 0.43
Bacterial Enzyme-Mediated Dopamine Precursor Synthesis
Score: 0.38
ACSL4-Driven Ferroptotic Priming in Disease-Associated Micro
Score: 0.89
← Prev
pg 7/8
Next →
Related Analyses (30)
Does SYK activation provide neuroprotection or exacerbate ne
neurodegeneration · archived
Neuroinflammation and microglial priming in early AD
neurodegeneration · completed
Neuroinflammation and microglial priming in early Alzheimer'
neurodegeneration · archived
Astrocyte Reactivity Subtypes in Neurodegeneration
neurodegeneration · archived
What are the optimal timing windows for TREM2 agonism vs ant
neurodegeneration · archived
Immune atlas neuroinflammation analysis in neurodegeneration
Neuroinflammation · completed
TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · completed
Immune atlas neuroinflammation analysis in neurodegeneration
Neuroinflammation · archived
Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · archived
Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · archived
Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived
Neuroinflammation resolution mechanisms and pro-resolving me
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed
Protein aggregation cross-seeding across neurodegenerative d
neurodegeneration · completed
Mechanistic role of APOE in neurodegeneration
neurodegeneration · archived
Lipid raft composition changes in synaptic neurodegeneration
neurodegeneration · completed
SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas
neurodegeneration · completed
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
Synaptic pruning by microglia in early AD
neurodegeneration · archived
Mitochondrial transfer between astrocytes and neurons
neurodegeneration · archived
Epigenetic clocks and biological aging in neurodegeneration
neurodegeneration · archived
Perivascular spaces and glymphatic clearance failure in AD
neurodegeneration · archived
Epigenetic reprogramming in aging neurons
neurodegeneration · archived
Extracellular vesicle biomarkers for early AD detection
neurodegeneration · archived
Cell type vulnerability in Alzheimers Disease (SEA-AD transc
neurodegeneration · archived
Cell type vulnerability in Alzheimers Disease (SEA-AD transc
neurodegeneration · archived
Senescent cell clearance as neurodegeneration therapy
neurodegeneration · archived
Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · archived
Sleep disruption as cause and consequence of neurodegenerati
neurodegeneration · archived
Selective vulnerability of entorhinal cortex layer II neuron
neurodegeneration · archived
Show 25 more
Related Experiments (30)
TREM2 KO amyloid pathology study
validation · completed · Score: 0.80
TREM2 KO amyloid pathology study
validation · completed · Score: 0.80
TREM2 KO amyloid pathology study
validation · completed · Score: 0.80
TREM2 KO amyloid pathology study
validation · in_progress · Score: 0.80
TREM2 KO amyloid pathology study
validation · completed · Score: 0.80
TREM2 KO amyloid pathology study
validation · completed · Score: 0.80
TREM2 KO amyloid pathology study
validation · in_progress · Score: 0.20
TREM2 Agonist Therapy for Parkinson's Disease — Experimental
validation · proposed · Score: 0.45
Microglial TREM2 Agonist In Vivo Efficacy
validation · proposed · Score: 0.45
TREM2 Function in Alzheimer's Disease — From Risk Variant to
validation · proposed · Score: 0.45
Mixed Pathology Effects on Parkinson's Disease Progression a
clinical · proposed · Score: 0.40
FTLD-Tau vs FTLD-TDP In Vivo Biomarker Differentiation
clinical · proposed · Score: 0.40
Proposed experiment from debate on Synaptic pruning by micro
falsification · proposed · Score: 0.40
Microglial Contributions to Huntington's Disease Pathogenesi
validation · proposed · Score: 0.40
Proposed experiment from debate on Synaptic pruning by micro
falsification · proposed · Score: 0.40
Macroautophagy Dysfunction in PD - Experiment Design
clinical · proposed · Score: 0.40
Non-Motor Symptom Progression in Parkinson's Disease — Mecha
clinical · proposed · Score: 0.40
DLB Treatment Response Biomarkers — Predicting Cholinesteras
clinical · proposed · Score: 0.40
CBS vs PSP Phenotype Determinants — Single-Nucleus Multi-Omi
validation · proposed · Score: 0.40
s:** - GPR32 knockout in microglia should worsen neuroinflam
falsification · proposed · Score: 0.40
Genetic Risk Modifiers in DLB Phenotype
clinical · proposed · Score: 0.40
DLB Cognitive Fluctuation Mechanism Experiment
clinical · proposed · Score: 0.40
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri
clinical · proposed · Score: 0.40
s:** - Compare tau strain spreading in EXT1/EXT2 conditional
falsification · proposed · Score: 0.40
Experiment: Autoimmune Hypothesis Testing in AD
clinical · proposed · Score: 0.40
Why Does Amyloid Removal Only Slow Decline 27%? — Mechanisti
clinical · proposed · Score: 0.40
AD Amyloid-Resilient Phenotype Study — Why Some amyloid-Posi
clinical · proposed · Score: 0.40
Microglial Aging and Immune Memory in Neurodegeneration — Tr
validation · proposed · Score: 0.40
Anti-Tau Antibody vs ASO/Gene Therapy — Comparative Efficacy
validation · proposed · Score: 0.40
Show 25 more
See Also (15)
Swedish BioFINDER 2 Study: Biomarkers and Neurodegenera
clinical · Pages share 139 hypotheses
Rotigotine and Rivastigmine Combination Therapy for Alz
clinical · Pages share 10 hypotheses
Liquid Biopsy in Neurodegeneration
biomarker · Pages share 139 hypotheses
A Phase 3, Randomised, Double-blinded, Placebo-controll
clinical · Pages share 11 hypotheses
Neuroimaging for Parkinsonian Syndromes (NCT03872102)
clinical · Pages share 27 hypotheses
Olfactory Mucosa, Blood and Urine for Identification of
clinical · Pages share 139 hypotheses
Cell-Free DNA Biomarkers in Neurodegeneration
biomarker · Pages share 139 hypotheses
IL-6 (Interleukin-6) in Neurodegeneration
biomarker · Pages share 139 hypotheses
Metabolomic Biomarkers in Neurodegeneration
biomarker · Pages share 139 hypotheses
Neuroimaging Biomarkers for Neurodegeneration
biomarker · Pages share 139 hypotheses
BEACoN Study - Biomarker Exploration in Aging, Cognitio
clinical · Pages share 139 hypotheses
Exosomal Biomarkers in Neurodegeneration
biomarker · Pages share 139 hypotheses
Exosomal miR-155 in Neurodegeneration
biomarker · Pages share 139 hypotheses
Synaptic Biomarkers in Neurodegeneration
biomarker · Pages share 139 hypotheses
Beta-Propeller Protein-Associated Neurodegeneration (BP
disease · Pages share 139 hypotheses
Show 10 more
Knowledge Graph (8 edges)
TREM2 R47H variant
impairs
microglial amyloid clearance
TREM2 agonism
causes
cerebral amyloid angiopathy
TREM2 agonism
protective_against
neurodegeneration
TREM2 deficiency
exacerbates
tau hyperphosphorylation
TREM2
inhibits
complement-mediated synapse loss
TREM2
regulates
C1QA
TREM2
regulates
microglial polarization states
TREM2
modulates
C1q
Community Feedback
⬆ Upvote
0
⬇ Downvote
0 upvotes · 0 downvotes
Post Comment
⚠ Flag Error
✏ Suggest Edit
💬 0 comments
⚠ 0 flags
✏ 0 edit suggestions
No comments yet. Be the first to comment!
View all feedback (JSON)
💬 Discussion (Talk page)
Loading comments...
Public annotations (0)
Annotate on Hypothes.is →
No public annotations yet.